The Company’s lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin's antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils. Immutrin was co-founded by Cambridge Innovation Capital, academic founders Professor Sir Mark Pepys FRS, Nobel Laureate Sir Gregory Winter FRS and Professor Daniel Christ and is built on decades of scientific and clinical leadership in amyloidosis combined with groundbreaking antibody expertise in drug development. Immutrin is led by an experienced management team and supported by other leading global investors including Frazier Life Sciences, F-Prime, Qiming Venture Partners and SR One.
We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.
© 2025 Cambridge Innovation Capital.
All rights reserved